original articles

Annals of Oncology

4.

5.

6. 7.

8. 9.

11.

12. Du Bois A, Ewald-Riegler N, de Gregorio N et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 2013; 49: 1905–1914. 13. Uzan C, Kane A, Rey A et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010; 21: 55–60. 14. Tavassoli FA, Devilee P. World Health Organization. Classification of the Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003. 15. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263–264. 16. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988; 62: 2212–2222. 17. Zanetta G, Rota S, Chiari S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19: 2656–2664. 18. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 2002; 86: 34–37. 19. Palomba S, Falbo A, Del Negro S et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod 2010; 25: 1966–1972.

Annals of Oncology 25: 171–176, 2014 doi:10.1093/annonc/mdt481 Published online 3 December 2013

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma L. Weiss1,†, T. Melchardt1, †, S. Habringer1, A. Boekstegers1, C. Hufnagl1, D. Neureiter2, G. Hopfinger1, R. Greil1 & A. Egle1* 1

Department of Internal Medicine III, Paracelsus Medical University, Salzburg; 2Institute of Pathology, Paracelsus Medical University, Salzburg, Austria

Received 1 July 2013; revised 24 September 2013; accepted 26 September 2013

Background: Obesity is a well-known risk factor for the development of several types of cancer including lymphomas, but its influence on the course of disease is fairly unknown. Recently, a retrospective cancer registry analysis demonstrated significantly prolonged survival for overweight and obese patients with diffuse large B-cell lymphoma (DLBCL). The study population almost exclusively consisted of male US American patients of lower socioeconomic status and onefifth of patients received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy without rituximab. Therefore, it remains unclear if these results can be extrapolated to the general DLBCL population. Patients and methods: This retrospective single-center analysis included 183 unselected DLBCL patients who were treated with rituximab and standard-dosed anthracycline-based chemoimmunotherapy as first-line therapy between January 2004 and December 2012. Patients were stratified by body mass index (BMI) into ‘low BMI’ (

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

Obesity is a well-known risk factor for the development of several types of cancer including lymphomas, but its influence on the course of disease is ...
184KB Sizes 0 Downloads 0 Views